| P50 | author | Mario Alberto Ugo Stampanoni Bassi | Q85651614 |
| | Ennio Iezzi | Q57310700 |
| P2093 | author name string | Diego Centonze | |
| | Roberta Morace | |
| | Andrea Sancesario | |
| P2860 | cites work | Inhibitory control of the GABAergic transmission in the rat neostriatum by D2 dopamine receptors | Q73465262 |
| | Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 |
| | N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor | Q21093349 |
| | Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade | Q24561819 |
| | Human cannabinoid pharmacokinetics | Q24652736 |
| | Looking for the role of cannabinoid receptor heteromers in striatal function | Q24658338 |
| | Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders | Q26823267 |
| | Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics | Q27336419 |
| | Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 |
| | The enigmatic pharmacology of GPR55 | Q28235873 |
| | Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus | Q28268567 |
| | Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 |
| | The molecular logic of endocannabinoid signalling | Q29615356 |
| | International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 |
| | Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. | Q30373216 |
| | Progress in understanding the factors regulating reversibility of long-term potentiation | Q32113661 |
| | Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 |
| | Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. | Q33890236 |
| | Endocannabinoid signaling in the brain | Q34125520 |
| | Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids | Q34166712 |
| | Cannabis and the brain | Q34199483 |
| | Endocannabinoid signaling and synaptic function | Q34304094 |
| | Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms | Q34349067 |
| | Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 |
| | Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study | Q34409345 |
| | Evaluation of Phytocannabinoids from High Potency Cannabis sativa using In Vitro Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2 | Q34533857 |
| | Endocannabinoids and basal ganglia functionality. | Q34673154 |
| | Cannabidiol for the treatment of psychosis in Parkinson's disease | Q34830827 |
| | CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 |
| | Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. | Q35070472 |
| | Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 |
| | The therapeutic potential of cannabinoids for movement disorders | Q35171113 |
| | Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease | Q35193305 |
| | The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders | Q35586641 |
| | Endocannabinoid signaling and long-term synaptic plasticity. | Q35679432 |
| | The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 |
| | GABA and Endocannabinoids Mediate Depotentiation of Schaffer Collateral Synapses Induced by Stimulation of Temperoammonic Inputs | Q35919442 |
| | Dopaminergic neurones: much more than dopamine? | Q36198137 |
| | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 |
| | LTP forms 1, 2 and 3: different mechanisms for the "long" in long-term potentiation | Q36733321 |
| | Biochemistry and pharmacology of endovanilloids | Q36756199 |
| | Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 |
| | Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. | Q36873051 |
| | Modulating the endocannabinoid system in human health and disease--successes and failures | Q36933683 |
| | Mechanisms of disease: basic-research-driven investigations in humans--the case of hyperkinetic disorders | Q36959855 |
| | A role of p38 mitogen-activated protein kinase in adenosine A₁ receptor-mediated synaptic depotentiation in area CA1 of the rat hippocampus | Q36963984 |
| | Presynaptic modulation by endocannabinoids | Q37026723 |
| | G protein-activated inwardly rectifying potassium channels mediate depotentiation of long-term potentiation. | Q37034843 |
| | Endocannabinoid-mediated control of synaptic transmission | Q37363621 |
| | The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 |
| | The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation | Q37532968 |
| | Anandamide and the vanilloid receptor (TRPV1). | Q37568663 |
| | Cannabinoids and Parkinson's disease. | Q37617450 |
| | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. | Q37734568 |
| | Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 |
| | Marijuana for parkinsonian tremor | Q41369366 |
| | Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 |
| | Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. | Q41720746 |
| | D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration | Q41833761 |
| | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism | Q42095959 |
| | Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease | Q42464432 |
| | Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 |
| | Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 |
| | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 |
| | Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 |
| | Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 |
| | Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. | Q43873792 |
| | Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 |
| | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 |
| | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease | Q44285779 |
| | Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 |
| | Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 |
| | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 |
| | Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. | Q44723162 |
| | Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function | Q44793025 |
| | A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission | Q44853701 |
| | Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 |
| | Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 |
| | The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 |
| | High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 |
| | A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 |
| | Endocannabinoid signaling dynamics probed with optical tools. | Q46750128 |
| | Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model | Q46789289 |
| | Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial | Q48065074 |
| | Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series | Q48105623 |
| | Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function | Q48189119 |
| | Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons | Q48202452 |
| | Prolonged adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical ischemia facilitates clathrin-mediated AMPA receptor endocytosis and long-lasting synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential r | Q48253332 |
| | Bidirectional long-term modification of synaptic effectiveness in the adult and immature hippocampus | Q48258130 |
| | Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 |
| | Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 |
| | Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease | Q48923652 |
| | Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. | Q49059668 |
| | Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 |
| | Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 |
| | A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses | Q73176506 |
| P433 | issue | 1 | |
| P921 | main subject | cannabinoids | Q422936 |
| | Parkinson's disease | Q11085 |
| P304 | page(s) | 21-29 | |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | Cannabis and cannabinoid research | Q27727510 |
| P1476 | title | Cannabinoids in Parkinson's Disease | |
| P478 | volume | 2 | |